吉西他滨联合顺铂治疗50例蒽环类耐药性晚期乳腺癌

目的：观察吉西他滨(健择)联合顺铂方案治疗蒽环类耐药性晚期乳腺癌的疗效与安全性。方法：2000年1月—2003年4月以本法治疗蒽环类耐药性晚期乳腺癌50例。中位化疗周期数3周期(2—4周期)。结果：可评价疗效47例，CR2例(4．3％)，PR18例(38．3％)，SD18例(38．3％)，PD9例(19．1％)，总有效率(CR PR)42．6％，中位肿瘤进展时间(TTP)4．5月。主要毒性恶心、呕吐与骨髓抑制。结论：吉西他滨和顺铂联合方案治疗蒽环类耐药性晚期乳腺癌疗效较好，使用方便，毒性反应较轻，是蒽环类耐药性乳腺癌的有效解救治疗方案。

Gemcitabine plus cisplatin for the treatment of anthracycine-resistant advanced breast cancer

Purpose:To evaluate the efficacy and safety of combination chemotherapy of gemcitabine(GEM) and cisplatin(DDP) for anthracycine(ANT)-resistant advanced breast cancer(ABC). (GEM 1 200 mg/m 2 on day1 and 8,DDP 30mg/m 2 on day 3 to 5 in cycles of 21 days) Methods:From January 2000 to April 2003,fifty patients with ANT-resistant ABC were treated with combination chemotherapy of GEM and DDP. The median number of cycles was 3(range 2-4). Results:The overall response rate was 42.6%,The median time to progression was 4.5 months. The main side effect included gastrointestinal and hematologic toxicities,related grade 3 to 4 clinical adverse effect was nausea and vomiting in 12 cases (24%),anemia in 2 cases (4), leukopenia in 7 cases (14%),neutropenia in 4 cases (8%) and thrombocytopenia in 16 cases (32%).Conclusions:GEM and DDP combination is active in ANT-resistant ABC with an acceptable toxicity pattern and may well represent an interesting therapeutic choice after ANT regimen.